Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ISB 2001 |
| Synonyms | |
| Therapy Description |
ISB 2001 is a trispecific T-cell engager targeting CD3 on T cells and BCMA and CD38 on tumor cells, which potentially decreases tumor growth (Blood (2022) 140 (Supplement 1): 858-859). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ISB 2001 | ISB2001|ISB-2001 | CD3 Antibody 119 CD38 Antibody 21 TNFRSF17 Antibody 22 | ISB 2001 is a trispecific T-cell engager targeting CD3 on T cells and BCMA and CD38 on tumor cells, which potentially decreases tumor growth (Blood (2022) 140 (Supplement 1): 858-859). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05862012 | Phase I | ISB 2001 | Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | Recruiting | USA | AUS | 1 |